非对称的二甲基瓜尼迪诺瓦莱里克酸作为早期高甘油三血症和失脂血症的独立相关风险因素
Yueyuan Han1,2, Qianling Xiong3, Jiahui Wang1,2
1Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, China.
概括
不对称二甲基瓜尼迪诺瓦莱里克酸 (ADGV) 的较高水平与高血糖三血症 (HTG) 的风险增加有关. ADGV促进肝脏中的甘油三积累,有助于HTG的发展.
科学领域:
- 代谢性疾病研究研究.
- 生物化学 生物化学
- 心血管疾病的危险因素
背景情况:
- 过高甘油三血症 (HTG) 是心血管疾病,代谢综合征和2型糖尿病的重要危险因素.
- 早期检测HTG是具有挑战性的,因为三甘油水平波动和长期预测值不佳.
研究的目的:
- 调查非对称二甲基瓜尼迪诺瓦莱里克酸 (ADGV) 在高甘油三血症 (HTG) 中的作用.
- 用队列数据和细胞实验分析ADGV水平与HTG风险之间的关联.
主要方法:
- 来自中国南部的横截面队列 (n=588) 的量化循环ADGV水平.
- 在中国北部的一组 (n=348,1.8年随访) 中评估了ADGV和事件HTG之间的潜在关联.
- 进行了体外肝细胞实验,以探索ADGV在肝脏甘油三代谢中的机制.
主要成果:
- 较高的ADGV水平与HTG风险增加显著相关,独立于其他因素.
- 通过刺激新的脂肪酸合成,ADGV促进了肝细胞中的甘油三积累.
- ADGV调节了参与脂质发生的关键代谢基因 (ACC,CPT1α,PGC1α).
结论:
- 循环较高的ADGV独立地与流行和发生的高甘油三血症有关.
- 肝细胞研究支持ADGV在促进肝脂发生的作用.
- ADGV可以作为HTG的潜在生物标志物或治疗标.
相关概念视频
Atherosclerosis III: Management
540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Coronary Artery Disease I: Introduction
1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Drug Toxicity: Risk factors
68
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
68
Coronary Artery Disease IV: Preventive Measures
789
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Atherosclerosis I: Introduction
1.7K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K


